Can I read PD-1/PD-L1 inhibitors plus carboplatin and paclitaxel compared with carboplatin and paclitaxel in primary advanced or recurrent endometrial cancer: a systematic review and meta-analysis of randomized clinical trials on EtoBox?

PD-1/PD-L1 inhibitors plus carboplatin and paclitaxel compared with carboplatin and paclitaxel in primary advanced or recurrent endometrial cancer: a systematic review and meta-analysis of randomized clinical trials by Francisco Cezar Aquino de Moraes; Eric Pasqualotto; Lucca Moreira Lopes; Maria Eduarda Cavalcanti Souza; Anna Luíza Soares de Oliveira Rodrigues; Artur Menegaz de Almeida; Carlos Stecca; Marianne Rodrigues Fernandes; Ney Pereira Carneiro dos Santos is a Medicine article available to read on EtoBox.

What is PD-1/PD-L1 inhibitors plus carboplatin and paclitaxel compared with carboplatin and paclitaxel in primary advanced or recurrent endometrial cancer: a systematic review and meta-analysis of randomized clinical trials about?

## Background Paclitaxel and carboplatin is the standard chemotherapy for the treatment of advanced or recurrent endometrial cancer. However, the benefit of adding programmed cell death 1 (PD-1)/programmed death ligand 1 (PD-L1) inhibitors to chemotherapy is still unclear. ## Method We searched PubMed, Scopus, Cochrane, and Web of Science databases for randomized controlled trials that investigated PD-1/PD-L1 inhibitors plus carboplatin and paclitaxel compared with carboplatin and paclitaxel in primary advanced or recurrent endometrial cancer. We computed hazard ratios (HRs) or risk ratios (RRs) for binary endpoints, with 95% confidence intervals (CIs). We used DerSimonian and Laird random-effect models for all endpoints. Heterogeneity was assessed using I^2^ statistics. R, version 4.2.3, was used for statistical analyses. ## Results A total of three studies and 1,431 patients were included. Compared with carboplatin plus paclitaxel-based chemotherapy, progression-free survival (PFS) rate (HR 0.32; 95% CI 0.23–0.44; __p__ < 0.001) and overall survival (OS) at 30 months (RR 3.13; 95% CI 1.26–7.78; __p__ = 0.01) were significant in favor of the PD-1/PD-L1 inhibitors plus carboplatin

Who reads PD-1/PD-L1 inhibitors plus carboplatin and paclitaxel compared with carboplatin and paclitaxel in primary advanced or recurrent endometrial cancer: a systematic review and meta-analysis of randomized clinical trials?

Author

Francisco Cezar Aquino de Moraes; Eric Pasqualotto; Lucca Moreira Lopes; Maria Eduarda Cavalcanti Souza; Anna Luíza Soares de Oliveira Rodrigues; Artur Menegaz de Almeida; Carlos Stecca; Marianne Rodrigues Fernandes; Ney Pereira Carneiro dos Santos

Publisher

Springer Science and Business Media LLC

Published

2023

Field

Medicine (Health Sciences)